Integra Lifesciences Holdings Corp

Integra Lifesciences Holdings Corp

IART

Get informed when a big investor buys or sells

+ Follow
Market Cap$1.25B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Integra Lifesciences Holdings CorpIntegra Lifesciences Holdings Corp-2.5--48%0.82
$12.00

Target Price by Analysts

25.5% downsideIntegra Lifesciences Holdings Target Price DetailsTarget Price
$15.94

Current Fair Value

1% downside

Overvalued by 1% based on the discounted cash flow analysis.

Share Statistics

Market cap$1.25 Billion
Enterprise Value$3.06 Billion
Dividend Yield$- (-)
Earnings per Share$-6.73
Beta1.08
Outstanding Shares76,951,000

Return

Return on Equity-47.56%ROE
Return on Assets-13.86%
Return on Invested Capital2.47%

Valuation & Multiples

P/E Ratio-2.49P/E Ratio
PEG3.05PEG
Price to Sales0.77Price to Sales
Price to Book Ratio1.24Price to Book Ratio
Enterprise Value to Revenue1.86
Enterprise Value to EBIT38.36
Enterprise Value to Net Income-7
Total Debt to Enterprise0.67
Debt to Equity1.97Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
May 5, 2026
EPS Estimate
$0.41
Average shareholder expectation
Revenue Estimate
$381.81 M
Average shareholder expectation

Next Earnings Call

Expected Date
July 30, 2026
EPS Estimate
$0.49
Average shareholder expectation
Revenue Estimate
$417.62 M
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.00000%
Total Calls-
Total Puts-

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %97.45% 1.06%
Total Invested$704.70M 23.36%
Investors Holding201 7.00%

ESG Score

No data

About Integra Lifesciences Holdings Corp

CEO: Peter Arduini

Relevant Senate Committees

Joint Committee on Taxation

This committee's role in providing official revenue estimates and technical analysis for all tax legislation gives its members crucial non-public material information that directly influences corporate tax structures and financial planning for companies like Integra Lifesciences.

Finance

Controlling taxation, trade, and entitlement spending (e.g., Medicare), this committee directly impacts Integra Lifesciences' profitability through tax policy, global supply chains and sales through trade policy, and a major customer segment (healthcare) through entitlement funding.

Appropriations

This committee directly allocates discretionary federal spending. Its subcommittees determine precise funding for scientific research, healthcare programs, and government agencies that are major customers for Integra Lifesciences' products.

Health, Education, Labor, and Pensions

This committee regulates the FDA (critical for medical device approval, which includes many analytical lab instruments) and influences NIH funding, a major source of demand for Integra Lifesciences' products in research settings.

Judiciary

This committee's oversight of intellectual property (patents for instruments, methods) and antitrust laws is critically important for a manufacturing and R&D-intensive company like Integra Lifesciences, directly affecting its legal environment and market competition.